Equities analysts expect First Wave BioPharma, Inc. (NASDAQ:FWBI – Get Rating) to report earnings of ($0.39) per share for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have provided estimates for First Wave BioPharma’s earnings, with the highest EPS estimate coming in at ($0.25) and the lowest estimate coming in at ($0.53). First Wave BioPharma reported earnings of ($1.40) per share in the same quarter last year, which would indicate a positive year over year growth rate of 72.1%. The company is expected to report its next earnings results on Monday, January 1st.
According to Zacks, analysts expect that First Wave BioPharma will report full-year earnings of ($1.34) per share for the current financial year, with EPS estimates ranging from ($1.59) to ($1.08). For the next year, analysts forecast that the company will report earnings of ($0.64) per share, with EPS estimates ranging from ($0.78) to ($0.50). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of research firms that cover First Wave BioPharma.
Separately, Zacks Investment Research raised shares of First Wave BioPharma from a “hold” rating to a “buy” rating and set a $1.50 target price on the stock in a report on Wednesday, January 19th.
First Wave BioPharma stock opened at $0.68 on Tuesday. The firm has a market capitalization of $11.32 million, a P/E ratio of -0.07 and a beta of 1.61. The stock has a fifty day moving average price of $1.13 and a two-hundred day moving average price of $1.64. First Wave BioPharma has a 52-week low of $0.66 and a 52-week high of $10.70.
About First Wave BioPharma (Get Rating)
First Wave BioPharma, Inc, a clinical-stage biopharmaceutical company, specializes in the development of targeted, non-systemic therapies for gastrointestinal diseases. The company is advancing a therapeutic development pipeline populated with various clinical stage programs built around its two proprietary technologies, known as niclosamide, an oral small molecule with anti-viral and anti-inflammatory properties, and the biologic adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients.
- Get a free copy of the StockNews.com research report on First Wave BioPharma (FWBI)
- Rite Aid Stock is Getting Cheap Enough to Buy Here
- Analysts Reel In Netflix Targets Ahead Of Q1 Earnings
- MarketBeat Podcast: Making Money in the Red-Hot Housing Market
- Banking On Bank Of America
- Major Shareholder Bets Big On Nielson Holdings plc
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for First Wave BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for First Wave BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.